First Time Loading...

Northeast Pharmaceutical Group Co Ltd
SZSE:000597

Watchlist Manager
Northeast Pharmaceutical Group Co Ltd Logo
Northeast Pharmaceutical Group Co Ltd
SZSE:000597
Watchlist
Price: 4.81 CNY -2.24% Market Closed
Updated: May 16, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Balance Sheet

15.3B
+5%
Assets
Growth Rates:
1 Year
+11%
3 Years
+26%
5 Years
+30%
7 Years
+56%
10 Years
+102%
10.3B
+6%
Liabilities
Growth Rates:
1 Year
+11%
3 Years
+26%
5 Years
+25%
7 Years
+38%
10 Years
+70%
5B
+3%
Equity
Growth Rates:
1 Year
+9%
3 Years
+25%
5 Years
+44%
7 Years
+116%
10 Years
+232%

Balance Sheet Decomposition
Northeast Pharmaceutical Group Co Ltd

15.3B
Assets
10.3B
Liabilities
15.3B
Assets
10.3B
Liabilities
Current Assets 9.8B
Cash & Short-Term Investments 2.8B
Receivables 2.6B
Other Current Assets 4.4B
Non-Current Assets 5.5B
PP&E 4.5B
Intangibles 850.6m
Other Non-Current Assets 128.8m
Current Liabilities 9.6B
Accounts Payable 1.4B
Accrued Liabilities 99.8m
Short-Term Debt 5.9B
Other Current Liabilities 2.1B
Non-Current Liabilities 716.9m
Long-Term Debt 181.3m
Other Non-Current Liabilities 535.6m

Balance Sheet
Northeast Pharmaceutical Group Co Ltd

Rotate your device to view
Balance Sheet
Currency: CNY
Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022 Dec-2023
Assets
Cash & Cash Equivalents
1 766
1 707
1 773
1 227
804
1 021
1 481
1 221
2 126
2 767
Cash
5
4
4
9
1
0
0
1 221
2 126
2 767
Cash Equivalents
1 761
1 703
1 769
1 218
803
1 021
1 481
0
0
0
Total Receivables
1 254
1 186
1 665
2 101
2 867
2 888
2 691
2 797
2 756
2 617
Accounts Receivables
711
734
1 078
1 418
1 848
1 819
1 719
1 851
1 980
1 821
Other Receivables
543
452
587
683
1 019
1 069
972
946
776
796
Inventory
978
862
1 092
1 353
1 271
1 284
1 253
1 247
1 220
1 364
Other Current Assets
138
144
509
890
650
687
128
1 535
1 933
3 035
Total Current Assets
4 137
3 898
5 040
5 571
5 593
5 879
5 553
6 799
7 931
9 783
PP&E Net
3 597
3 901
3 828
4 001
5 155
5 622
5 551
5 298
4 915
4 511
PP&E Gross
3 597
3 901
3 828
4 001
5 155
5 622
5 551
5 298
4 915
4 511
Accumulated Depreciation
1 707
1 819
2 022
2 235
2 483
2 378
2 791
3 193
3 502
3 992
Intangible Assets
802
844
868
914
854
920
944
952
829
824
Goodwill
0
0
0
37
26
26
26
26
26
26
Long-Term Investments
2
2
2
2
2
0
0
0
0
0
Other Long-Term Assets
36
47
52
68
88
93
91
104
110
129
Other Assets
0
0
0
37
26
26
26
26
26
26
Total Assets
8 573
N/A
8 693
+1%
9 790
+13%
10 593
+8%
11 719
+11%
12 540
+7%
12 166
-3%
13 180
+8%
13 810
+5%
15 274
+11%
Liabilities
Accounts Payable
727
842
913
992
1 465
1 618
1 693
1 790
1 780
1 398
Accrued Liabilities
23
21
34
45
44
48
48
51
81
100
Short-Term Debt
3 114
3 376
3 503
3 993
4 257
4 206
3 806
4 242
4 777
5 928
Current Portion of Long-Term Debt
7
7
7
480
42
0
0
220
60
712
Other Current Liabilities
540
386
477
530
842
2 027
1 769
1 895
1 725
1 432
Total Current Liabilities
4 412
4 631
4 933
6 040
6 651
7 899
7 316
8 199
8 423
9 568
Long-Term Debt
100
180
600
235
0
150
200
218
256
181
Deferred Income Tax
6
6
6
6
6
6
6
5
5
5
Minority Interest
97
112
120
114
122
107
142
147
154
170
Other Liabilities
1 293
1 474
1 816
1 764
1 469
567
522
467
413
360
Total Liabilities
5 909
N/A
6 403
+8%
7 476
+17%
8 159
+9%
8 248
+1%
8 729
+6%
8 185
-6%
9 036
+10%
9 251
+2%
10 285
+11%
Equity
Common Stock
475
475
475
475
570
905
1 351
1 348
1 434
1 429
Retained Earnings
421
37
61
180
375
547
561
651
984
1 200
Additional Paid In Capital
1 770
1 778
1 778
1 779
2 525
2 574
2 188
2 146
2 375
2 468
Unrealized Security Profit/Loss
0
0
0
0
0
0
0
0
1
1
Treasury Stock
0
0
0
0
0
215
117
0
235
111
Other Equity
1
0
1
0
1
0
1
2
2
3
Total Equity
2 664
N/A
2 289
-14%
2 314
+1%
2 434
+5%
3 471
+43%
3 811
+10%
3 981
+4%
4 144
+4%
4 559
+10%
4 988
+9%
Total Liabilities & Equity
8 573
N/A
8 693
+1%
9 790
+13%
10 593
+8%
11 719
+11%
12 540
+7%
12 166
-3%
13 180
+8%
13 810
+5%
15 274
+11%
Shares Outstanding
Common Shares Outstanding
1 054
1 054
1 054
1 054
1 265
1 348
1 351
1 348
1 348
1 388

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 137,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.